- Home
- SGMT vs INFU Comparison
SGMT vs INFU Comparison
Compare SGMT & INFU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SGMT | INFU |
|---|---|---|
| Founded | 2006 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.4M | 190.1M |
| IPO Year | 2021 | 2005 |
Fundamental Metrics
Financial Performance| Metric | SGMT | INFU |
|---|---|---|
| Price | $6.95 | $9.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 2 |
| Target Price | ★ $26.13 | $15.00 |
| AVG Volume (30 Days) | ★ 781.4K | 132.1K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 181.82 |
| EPS | N/A | ★ 0.05 |
| Revenue | $2,000,000.00 | ★ $143,436,000.00 |
| Revenue This Year | N/A | $3.20 |
| Revenue Next Year | N/A | $7.31 |
| P/E Ratio | ★ N/A | $181.00 |
| Revenue Growth | N/A | ★ 6.36 |
| 52 Week Low | $4.50 | $5.43 |
| 52 Week High | $11.41 | $11.04 |
Technical Indicators
Market Signals| Indicator | SGMT | INFU |
|---|---|---|
| Relative Strength Index (RSI) | 55.64 | 62.84 |
| Support Level | $6.26 | $8.59 |
| Resistance Level | $7.20 | $10.81 |
| Average True Range (ATR) | 0.33 | 0.43 |
| MACD | 0.05 | 0.10 |
| Stochastic Oscillator | 76.82 | 87.72 |
Price Performance
Historical ComparisonAbout SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
About INFU InfuSystems Holdings Inc.
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. The company's services are provided under two-reportable segments: Patient Services and Device Solutions. Maximum revenue is generated from its Patient Services segment, which provides Durable Medical Equipment (DME) and treatment consumables, handles order and delivery logistics, provides 24/7 nursing support relating to the provided equipment, assumes responsibility for third-party payer Durable Medical Equipment billing, and handles biomedical services for the Durable Medical Equipment. The Device Solutions segment includes equipment rental and sales, consumable sales, and biomedical support services.